NO20020979L - Selektive A2B-adenosinreseptorantagonister - Google Patents

Selektive A2B-adenosinreseptorantagonister

Info

Publication number
NO20020979L
NO20020979L NO20020979A NO20020979A NO20020979L NO 20020979 L NO20020979 L NO 20020979L NO 20020979 A NO20020979 A NO 20020979A NO 20020979 A NO20020979 A NO 20020979A NO 20020979 L NO20020979 L NO 20020979L
Authority
NO
Norway
Prior art keywords
selective
receptor antagonists
adenosine receptor
adenosine
antagonists
Prior art date
Application number
NO20020979A
Other languages
English (en)
Other versions
NO328489B1 (no
NO20020979D0 (no
Inventor
Italo O Biaggioni
Igor A Feoktistov
Jack N Wells
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of NO20020979D0 publication Critical patent/NO20020979D0/no
Publication of NO20020979L publication Critical patent/NO20020979L/no
Publication of NO328489B1 publication Critical patent/NO328489B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
NO20020979A 1999-08-31 2002-02-27 Nye forbindelser og anvendelse av disse for fremstilling av farmasoytiske preparater for behandling av blant annet astma og diar± NO328489B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15164999P 1999-08-31 1999-08-31
PCT/US2000/040751 WO2001016134A1 (en) 1999-08-31 2000-08-28 Selective antagonists of a2b adenosine receptors

Publications (3)

Publication Number Publication Date
NO20020979D0 NO20020979D0 (no) 2002-02-27
NO20020979L true NO20020979L (no) 2002-04-26
NO328489B1 NO328489B1 (no) 2010-03-01

Family

ID=22539669

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020979A NO328489B1 (no) 1999-08-31 2002-02-27 Nye forbindelser og anvendelse av disse for fremstilling av farmasoytiske preparater for behandling av blant annet astma og diar±

Country Status (22)

Country Link
EP (1) EP1208100B1 (no)
JP (1) JP3914434B2 (no)
KR (1) KR100502757B1 (no)
CN (1) CN1178940C (no)
AR (1) AR029178A1 (no)
AT (1) ATE236160T1 (no)
AU (1) AU760071B2 (no)
BR (1) BR0013673A (no)
CA (1) CA2383351C (no)
DE (1) DE60001969T2 (no)
DK (1) DK1208100T3 (no)
ES (1) ES2190422T3 (no)
HK (1) HK1049835B (no)
IL (2) IL148366A0 (no)
MX (1) MXPA02002262A (no)
NO (1) NO328489B1 (no)
NZ (1) NZ517546A (no)
PT (1) PT1208100E (no)
TR (1) TR200201132T2 (no)
TW (1) TWI262921B (no)
WO (1) WO2001016134A1 (no)
ZA (1) ZA200201650B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
DE60206756T2 (de) * 2001-06-29 2006-07-13 CV Therapeutics, Inc., Palo Alto Purin derivate als a2b adenosin rezeptor antagonisten
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
EP1646390B1 (en) * 2003-07-22 2008-10-08 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
US20070219178A1 (en) * 2003-12-04 2007-09-20 Eisai Co., Ltd. Preventive or therapeutic agents for multiple sclerosis
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
EP1799221A1 (en) * 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
CN101076343A (zh) 2004-10-20 2007-11-21 Cv医药有限公司 A2a腺苷受体激动剂的应用
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
US11370792B2 (en) 2015-12-14 2022-06-28 Raze Therapeutics, Inc. Caffeine inhibitors of MTHFD2 and uses thereof
US20200345725A1 (en) 2019-01-11 2020-11-05 Omeros Corporation Methods and Compositions for Treating Cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
ATE194345T1 (de) * 1990-12-21 2000-07-15 Beecham Group Plc Xanthinderivate
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
CA2383351C (en) 2005-11-01
PT1208100E (pt) 2003-07-31
KR20020041419A (ko) 2002-06-01
AR029178A1 (es) 2003-06-18
BR0013673A (pt) 2002-05-28
DK1208100T3 (da) 2003-06-30
ZA200201650B (en) 2003-05-28
NZ517546A (en) 2003-10-31
CA2383351A1 (en) 2001-03-08
ATE236160T1 (de) 2003-04-15
IL148366A0 (en) 2002-09-12
HK1049835B (zh) 2005-04-08
TWI262921B (en) 2006-10-01
ES2190422T3 (es) 2003-08-01
AU760071B2 (en) 2003-05-08
NO328489B1 (no) 2010-03-01
JP2003508398A (ja) 2003-03-04
DE60001969D1 (de) 2003-05-08
HK1049835A1 (en) 2003-05-30
EP1208100B1 (en) 2003-04-02
CN1377352A (zh) 2002-10-30
KR100502757B1 (ko) 2005-07-22
TR200201132T2 (tr) 2002-08-21
CN1178940C (zh) 2004-12-08
MXPA02002262A (es) 2002-09-30
JP3914434B2 (ja) 2007-05-16
NO20020979D0 (no) 2002-02-27
EP1208100A1 (en) 2002-05-29
AU8034800A (en) 2001-03-26
DE60001969T2 (de) 2004-02-05
IL148366A (en) 2006-12-10
WO2001016134A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
ATE293627T1 (de) Adenosin a2a rezeptor antagonisten
IS5706A (is) Adenosín A3 viðtakastillar
HUP0401925A3 (en) A2b adenosine receptor antagonists
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
DE60209251D1 (de) Adenosine a2a receptor antagonisten
ATE256141T1 (de) N-pyrazol a2a rezeptor agonisten
ATE453647T1 (de) Adenosin a2a rezeptor antagonisten
DE60026169D1 (de) Selektive neurokinin-antagonisten
NO20020979L (no) Selektive A2B-adenosinreseptorantagonister
MXPA03004439A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina.
CY2010003I2 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
TWI365879B (en) A2b adenosine receptor antagonists
ATE280157T1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE60219196D1 (de) BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
EE200300260A (et) Kondenseeritud puriinderivaadid kui A1 adenosiiniretseptori antagonistid
NO20015662L (no) Oralt aktive A1-adenosinreseptorantagonister
SI1444233T1 (sl) Antagonisti adenozinskega receptorja A2B
MA26854A1 (fr) Antagonistes recepteurs de tachykinine non-peptidique
SI1401837T1 (sl) Purinski derivati kot antagonisti adenozinskega receptorja A2B
SE0003996D0 (sv) Receptorantagonister

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees